Ophthalmic Complications Associated With...

Interview with Jonathan H. Lass, MD, author of Diabetes Severity in Cornea Donors and 1-Year Outcomes in Recipients in the Diabetes Endothelial Keratoplasty Study: A Secondary Analysis of a Randomized Clinical Trial. Hosted by Neil Bressler, MD. Related Content: Diabetes Severity ... Show More

Interview with Michael Kazim, MD, author of Why Metrics Matter in Thyroid Eye Disease: An Innovate TED Initiative. Hosted by Neil Bressler, MD. Related Content: Why Metrics Matter in Thyroid Eye Disease 

Interview with Rupesh Agrawal, MMed, MD, and James T. Rosenbaum, MD, authors of Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel. Hosted by Neil Bressler, MD. Related Content: Standardization of Retinal Vasculitis Terminology With C ... Show More

Dr. Peter Quiros joins host Dr. Amanda Redfern to discuss the recent JAMA Ophthalmology article "The Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," the first study to report a possible association between semaglutide (Wegovy, Ozempic, ... Show More

Dr. Drew Carey interviews medical student Jawad Muayad and Dr. Sami S. Dahr on the impact of systemic medications, including glucagon-like peptide-1 receptor agonists, fenofibrates, thiazolidinediones, and calcium channel blockers, on the risk of developing diabetic macular edema ... Show More

New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights ar ... Show More

Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed. 

On this podcast episode, I discuss the pharmacology, adverse effects, and drug interactions of semaglutide. Semaglutide has two primary uses: Type 2 diabetes and Weight Management – the dosing varies depending upon the indication. When using semaglutide, pay attention to GI adver ... Show More

Interview with Fasiha Kanwal, MD, MSHS, author of GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Hosted by Eve Rittenberg, MD, and Grace Yuan Zhang, MD Related Content: GLP-1 Rece ... Show More

<p class="MsoNormal">Dr. Edmund Tsui interviews authors Dr. Muhammad Z. Chauhan and Dr. Krishna S. Kishor on the risk of uveitis among patients starting topical glaucoma therapy. From their <em>Ophthalmology Glaucoma</em> article, "<a href= "https://www.ophthalmologyglaucoma.org/ ... Show More

Dr. Rajesh Rao discusses the risk factors for epiretinal membrane formation in patients with diabetes mellitus with Dr. Shinji Kakihara, first author of the Ophthalmology Science article, "Epiretinal Membrane Is Associated with Diabetic Retinopathy Severity and Cumulative Anti-VE ... Show More

<p dir="ltr">Ozempic. Developed as diabetes medication. Adopted as a weight loss drug. Eyed for its potential neuroprotective effects.</p> <p dir="ltr">Hollywood's popularization of Ozempic as a way to lose weight has made it one of the most widely-discussed drugs of our time, an ... Show More